Vancouver, BC — August 20, 2015- InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announces today the successful completion and validation of preclinical pain modelling.
Following the recently completed in silico work using InMed’s proprietary “IDP” platform to identify cannabinoid compounds for its orofacial pain program (see News Release dated March 18, 2015), InMed completed validation of the preclinical pain model using nerve growth factor (NGF) induced pain in rats. Preliminary data indicates that primary afferent neurons innervating the masseter muscles of female rats expressed CB1 and CB2 and these expressions were found in satellite glial cells in the trigeminal ganglion.
Dr. Sazzad Hossain, Chief Scientific Officer of Inmed Pharmaceuticals stated “these results suggest that in pain conditions where the level of NGF is elevated, pain is mediated, in part, by the reduction of the inhibitory input by the endo-cannabinoid system in the periphery. Peripheral application of cannabinoids may counter this effect and provide analgesic relief”.
InMed is currently conducting further preclinical works using selected cannabinoid compound compounds to develop a new therapy for orofacial pain.
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathways are the fundamental value drivers of the company.
For more information, visit www.inmedpharma.com.
ON BEHALF OF THE BOARD
InMed Pharmaceuticals Inc.
President and Chief Executive Officer
[email protected] / www.inmedpharma.com
Forward Looking Statements
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.